Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma
Zi–Ming Du MD, PhD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm SE-17177, Sweden
Zi–Ming Du and Chang–Wei Kou contributed equally to this work.
Search for more papers by this authorChang–Wei Kou MD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Zi–Ming Du and Chang–Wei Kou contributed equally to this work.
Search for more papers by this authorHai–Yun Wang MD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorMa–Yan Huang MD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorDing–Zhun Liao MD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorChun–Fang Hu MD, PhD
Institute for Cancer Studies, University of Birmingham, Birmingham, England, United Kingdom
Search for more papers by this authorJing Chen MD, PhD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorLi–Xu Yan MD, PhD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorLi–Fu Hu PhD
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm SE-17177, Sweden
Search for more papers by this authorIngemar Ernberg MD, PhD
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm SE-17177, Sweden
Search for more papers by this authorYi–Xin Zeng MD, PhD
State Key Laboratory of Oncology in South China, and Department of Experiment Research, Sun Yat–Sen University Cancer Center, Guangzhou, China
Search for more papers by this authorCorresponding Author
Jian–Yong Shao MD, PhD
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm SE-17177, Sweden
State Key Laboratory of Oncology in South China and Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People's Republic of China
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of ChinaSearch for more papers by this authorZi–Ming Du MD, PhD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm SE-17177, Sweden
Zi–Ming Du and Chang–Wei Kou contributed equally to this work.
Search for more papers by this authorChang–Wei Kou MD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Zi–Ming Du and Chang–Wei Kou contributed equally to this work.
Search for more papers by this authorHai–Yun Wang MD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorMa–Yan Huang MD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorDing–Zhun Liao MD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorChun–Fang Hu MD, PhD
Institute for Cancer Studies, University of Birmingham, Birmingham, England, United Kingdom
Search for more papers by this authorJing Chen MD, PhD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorLi–Xu Yan MD, PhD
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of China
Search for more papers by this authorLi–Fu Hu PhD
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm SE-17177, Sweden
Search for more papers by this authorIngemar Ernberg MD, PhD
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm SE-17177, Sweden
Search for more papers by this authorYi–Xin Zeng MD, PhD
State Key Laboratory of Oncology in South China, and Department of Experiment Research, Sun Yat–Sen University Cancer Center, Guangzhou, China
Search for more papers by this authorCorresponding Author
Jian–Yong Shao MD, PhD
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm SE-17177, Sweden
State Key Laboratory of Oncology in South China and Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People's Republic of China
State Key Laboratory of Oncology in South China and Department of Pathology, Sun Yat–Sen University Cancer Center, Guangzhou 510060, People's Republic of ChinaSearch for more papers by this authorAbstract
Background
Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine kinase and often aberrantly expressed in human cancers. However, Syk expression pattern has not yet been investigated in nasopharyngeal carcinoma (NPC).
Methods
Samples of 223 NPC tissues were immunohistochemically stained for Syk expression and survival analysis was then performed. Interaction and co-localization of Syk with Epstein–Barr virus encoded latent membrane protein 2A (LMP2A) was explored.
Results
High expression of Syk was detected in 24% of NPC cases, and correlated significantly with T classification, local recurrence, a lower 5-year survival rate, and a lower 5-year disease-free survival (DFS) rate. Syk expression was a significant, independent prognosis predictor for patients with NPC. LMP2A induced Syk expression in NPC and LMP2A high expression correlated with Syk high expression in NPC clinical samples.
Conclusion
High expression of Syk, which results partly from LMP2A expression in NPC, is associated with tumor recurrence and poor prognosis of patients with NPC. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| HED_21953_sm_SuppFig1.tif220.7 KB | Supporting Information Figure 1. The characteristics of the 1992 NPC staging system. The staging system is characterized according to the following model: T, primary tumor: T1, limited to the nasopharynx; T2, involvement of the nasal cavity, oropharynx, soft palatine, anterior cervical vertebrae soft tissue, and parapharyngeal space extension before the SO line (the SO line is between the styloid process and the midpoint on the posterior edge of the great occipital foramen);T3, extension over the SO line, involvement of the anterior or posterior cranial nerves alone, the base of the skull, the pterygoprocess zone, and the pterygopalatine fossa; T4, involvement of both anterior and posterior cranial nerves, parabasal sinus, cavernous sinus, orbit, infratemporal fossa, and direct invasion of the first or second cervical vertebrae; N, regional lymph node involvement: N0, no enlarged lymph nodes; N1, greatest dimension of upper neck lymph node <4 cm, movable; N2, lower neck lymph node or greatest lymph node dimension between 4 and 7 cm; N3, supraclavicular lymph node, lymph node greatest dimension >7 cm, fixed, or skin infiltration (the border between the upper neck and the lower neck is the inferior margin of the cricoid cartilage); M, distant metastasis: M0, absence of distant metastasis; M1, presence of distant metastasis; staging: Stage I, T1N0M0; Stage II, T2N0-N1M0, T0-T2N1M0; Stage III, T3N0-N2M0, T0-T3N2M0; Stage IVa, T4N0-N3M0, T0-T4N3M0; Stage IVb, M1. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Licitra L, Bernier J, Cvitkovic E, et al. Cancer of the nasopharynx. Crit Rev Oncol Hematol 2003; 45: 199–213.
- 2 Titcomb CP Jr. High incidence of nasopharyngeal carcinoma in Asia. J Insur Med 2001; 33: 235–238.
- 3 Kumar S, Mahanta J. Aetiology of nasopharyngeal carcinoma. A review. Indian J Cancer 1998; 35: 47–56.
- 4 Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004; 100: 1162–1170.
- 5 Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ. A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer 2000; 89: 242–247.
- 6
Heng DM,
Wee J,
Fong KW, et al.
Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma.
Cancer
1999;
86:
1912–1920.
10.1002/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 7 Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem 2001; 130: 177–186.
- 8 Fruehling S, Swart R, Dolwick KM, Kremmer E, Longnecker R. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein–Barr virus latency. J Virol 1998; 72: 7796–7806.
- 9 Lu J, Lin WH, Chen SY, et al. Syk tyrosine kinase mediates Epstein–Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 2006; 281: 8806–8814.
- 10 Toyama T, Iwase H, Yamashita H, et al. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett 2003; 189: 97–102.
- 11 Layton T, Stalens C, Gunderson F, Goodison S, Silletti S. Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am J Pathol 2009; 175: 2625–2636.
- 12 Yuan Y, Wang J, Li J, et al. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res 2006; 12: 6687–6695.
- 13 Kunze E, Wendt M, Schlott T. Promoter hypermethylation of the 14–3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. Int J Mol Med 2006; 18: 547–557.
- 14 Nakashima H, Natsugoe S, Ishigami S, et al. Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer. Cancer Lett 2006; 236: 89–94.
- 15 Luangdilok S, Box C, Patterson L, et al. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 2007; 67: 7907–7916.
- 16 Feldman AL, Sun DX, Law ME, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 2008; 22: 1139–1143.
- 17 Wilcox RA, Sun DX, Novak A, Dogan A, Ansell SM, Feldman AL. Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines. Leukemia 2010; 24: 229–232.
- 18 Baudot AD, Jeandel PY, Mouska X, et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009; 28: 3261–3273.
- 19 Uckun FM, Ozer Z, Qazi S, Tuel–Ahlgren L, Mao C. Polo-like- kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress. Br J Haematol 2010; 148: 714–725.
- 20 Min H, Hong M, Ma J, et al. A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys 1994; 30: 1037–1042.
- 21 Li YH, Hu CF, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 2008; 6: 1.
- 22 Du ZM, Hu CF, Shao Q, et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer 2009; 125: 1832–1841.
- 23 Kong QL, Hu LJ, Cao JY, et al. Epstein–Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 2010; 6: e1000940.
- 24 Lu J, Chen SY, Chua HH, et al. Upregulation of tyrosine kinase TKT by the Epstein–Barr virus transactivator Zta. J Virol 2000; 74: 7391–7399.
- 25 Szeles A, Falk KI, Imreh S, Klein G. Visualization of alternative Epstein–Barr virus expression programs by fluorescent in situ hybridization at the cell level. J Virol 1999; 73: 5064–5069.
- 26 Futterer K, Wong J, Grucza RA, Chan AC, Waksman G. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol 1998; 281: 523–537.
- 27 Brooks L, Yao QY, Rickinson AB, Young LS. Epstein–Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66: 2689–2697.
- 28 Merchant M, Caldwell RG, Longnecker R. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 2000; 74): 9115–9124.
- 29 Ikeda M, Longnecker R. The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling. Virology 2009; 385: 183–191.
- 30 Pegtel DM, Subramanian A, Sheen TS, Tsai CH, Golub TR, Thorley–Lawson DA. Epstein–Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol 2005; 79: 15430–15442.
Citing Literature
